AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03169504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug
Description: Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks.
Study NCT03169504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture plus conventional drug
Description: Both acupuncture and conventional drug will be used for 12 weeks treatment.
Study NCT02970474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Bolus
Description: Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
Study NCT02970474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Printed Bolus
Description: The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
Study NCT02391454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RunKeeper App
Description: Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
Study NCT02391454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT02391454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT00781287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-drug anti-HIV therapy
Description: 3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
Study NCT00781287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-drug anti-HIV therapy
Description: 3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
Study NCT00781287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg BID PO
Study NCT01827618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Study NCT02034370 — intervention group
Intervention type: DEVICE
Intervention: Lung-function spirometry test
Description: 5 minute lung function test performed once preoperatively and once postoperatively
Study NCT02034370 — intervention group
Intervention type: DEVICE
Intervention: Overnight sleep test
Description: Somte sleep monitor to be worn two nights before and the night of surgery.
Study NCT02370810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based internet-intervention for tinnitus
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
Study NCT02370810 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-based internet-intervention for tinnitus
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
Study NCT00584649 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: electrophysiology study and radiofrequency ablation
Description: stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
Study NCT01418989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra] Syringe
Description: Single dose administration with pre-filled syringe
Study NCT01418989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra] auto-injector
Description: Single dose administration with auto-injector
Study NCT02518490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire Lens
Description: Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
Study NCT02518490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
Study NCT02086123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: Bupivacaine + Fentanyl
Study NCT02086123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Analgesia (Intravenous)
Description: Dilaudid 0.2 -0.4 mg IV every 3 hours
Study NCT04256629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad
Study NCT04256629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo
Study NCT04256629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
Study NCT02738944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry Collaborative Care
Description: The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
Study NCT02738944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry Enhanced Referral
Description: The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home.
Study NCT04100668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensifree's Alpha sensor
Description: RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
Study NCT04100668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrow® arterial catheterization kit (Teleflex)
Description: Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
Study NCT04100668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor
Description: PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
Study NCT04882995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyillium fiber
Description: Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
Study NCT03753659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03753659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio Frequency Ablation (RFA)
Description: Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
Study NCT03753659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
Study NCT03753659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
Study NCT03753659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolisation (TACE)
Description: According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
Study NCT00477334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: oral; two 500 mg tablets twice a day; single day treatment
Study NCT00477334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; two tablets twice a day; single day treatment
Study NCT01452659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01452659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01452659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01452659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT05402930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiomammography
Description: Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR.
Study NCT01170611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACEMAKER SYMPHONY 2550
Study NCT02541123 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
Study NCT03562650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Fading
Description: Participants are asked to fade their three most common safety behaviors associated with their social anxiety
Study NCT03562650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered
Description: Participants are asked to try to increase their focus on the present.
Study NCT01293305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period
Study NCT01293305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period
Study NCT01293305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.
Study NCT01293305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.
Study NCT03234985 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological analyses
Description: Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
Study NCT03536143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical beremagene geperpavec
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Study NCT03536143 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study NCT02115516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
Study NCT02115516 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)
Study NCT05729178 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
Study NCT04460274 — intervention group
Intervention type: OTHER
Intervention: Model Building
Description: Model building
Study NCT04460274 — intervention group
Intervention type: OTHER
Intervention: Model validation
Description: Model validation
Study NCT02641600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic stockings
Description: Use of elastic stockings to alleviate patient symptoms
Study NCT02641600 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stockings
Description: Placebo stocking with pressure applied to the legs
Study NCT01347762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: nabilone titrated to 1 mg by mouth twice daily
Study NCT01347762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo capsule by mouth twice daily
Study NCT04451174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
Study NCT00827866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counselor-Initiated Tobacco Quit Line
Description: The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
Study NCT00827866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-Paced Tobacco Quit Line
Description: The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
Study NCT02216305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
Study NCT02216305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAL-RAR
Description: Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
Study NCT01115660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke education
Description: call by medication coach 2 weeks after hospital discharge
Study NCT00598143 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vignette, questionnaires and Saliva Samples
Description: The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
Study NCT00598143 — intervention group
Intervention type: BEHAVIORAL
Intervention: Urine Collection, Smoking cessation treatment
Description: Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
Study NCT03248154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera
Description: burn dressing
Study NCT03371381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757
Description: Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
Study NCT03371381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
Study NCT03371381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
Study NCT05525884 — intervention group
Intervention type: OTHER
Intervention: non-invasive method, Fibroscan
Description: Liver Ultrasound and transient elastography (FibroScan®)
Study NCT03018054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: once daily administration
Study NCT03018054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily administration
Study NCT02631512 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Woulgan Gel
Description: Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
Study NCT02631512 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intrasite Hydrogel
Description: Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
Study NCT00680784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT-500 Ketoprofen Topical Patch
Description: HKT-500 Ketoprofen Topical Patch
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 85 mg/m2
Description: 85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU; 2400 mg/m2
Description: 2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, 250 mg/m2
Description: 250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, 2400 mg/m2
Description: 2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
Study NCT00680784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch
Study NCT01210664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Description: The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
Study NCT00552240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir DF 300 mg QD
Description: 300 mg QD
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 50 mg/m2
Description: 50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and